Sermorelin is the first 29 amino acids of the body's 44-amino-acid growth hormone-releasing hormone — the minimum fragment needed to fully activate the GHRH receptor and trigger GH release. It earned FDA approval in 1997 under the brand name Geref, making it the first synthetic GH secretagogue to clear the regulatory bar. EMD Serono pulled it from the market in 2008 — not because of safety signals, but because the economics of manufacturing a niche peptide couldn't compete with established recombinant HGH products already entrenched in pediatric endocrinology.
That regulatory history gives sermorelin a distinct legal position among GH secretagogues in compounding today: prior FDA approval under 503A, no safety-related withdrawal.
The adult evidence is thin. The entire clinical case rests on Khorram et al. (1997): 19 elderly subjects, 16 weeks, single-blind. It recorded +1.26 kg lean mass in men (not women), no significant fat loss, no change in bone density. Set against tesamorelin's 816-patient Phase III program, the evidence gap is not subtle.
Where sermorelin occupies its own ground: a selective profile (no cortisol, ACTH, or prolactin elevation at standard doses in the cited data), the somatostatin feedback brake intact, and a milder GH stimulus that the practitioner literature pairs with recovery support during caloric restriction rather than aggressive visceral fat reduction. As FDA enforcement against compounded peptides tightened through 2026, sermorelin's prior-approval status drew more of the practitioner discussion.
| At a Glance | |
|---|---|
| Dosage | 200–300 mcg subcutaneous (injected under the skin), nightly. |
| Protocol | 8–12 weeks on, 2–4 weeks off. 30–60 minutes before bed, at least 2 hours fasted. |
| Results timeline | Sleep quality improvements may be noticeable within 1–2 weeks, GH and IGF-1 elevation becomes measurable within the first month, and body composition changes typically require 8–12 weeks of consistent use. |
| Side effects | Transient facial flushing is the most common, followed by mild injection site reactions and occasional peripheral tingling that resolves with dose reduction. |
| Regulatory status | FDA-approved in 1997 (Geref), commercially withdrawn in 2008 for business reasons — not safety. Available through compounding pharmacies with a prescription. WADA-prohibited. |
| Best stacked with | Tesamorelin — more potent GHRH analog if stronger GH stimulation is needed. GLP-1 agonists — metabolic synergy during caloric restriction. |
What Is Sermorelin?
The sermorelin peptide consists of the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH), which is naturally 44 amino acids long. Those 29 amino acids — sometimes written as GRF(1-29) — represent the minimum fragment needed to fully activate the GHRH receptor on the pituitary gland and trigger growth hormone release. It was FDA-approved in 1997 under the brand name Geref and commercially withdrawn in 2008 for manufacturing reasons, not safety concerns¹˒².
To put it simply: the brain already makes the full 44-amino-acid version of GHRH. Sermorelin is the active core of that molecule — the part that does the work — produced synthetically so it can be administered as an injection.
With a molecular weight of approximately 3,358 Da, the compound sits firmly in peptide territory. It is structurally unmodified against enzymatic breakdown, which gives it a short intravenous half-life of just 10-20 minutes¹˒². It clears from the bloodstream within about four hours, though the downstream growth hormone effects persist for roughly three hours after that initial receptor activation¹. The brevity is part of the design — it creates a crisp pulse of GH rather than a sustained elevation, closely mimicking what the pituitary does naturally during deep sleep.
How Sermorelin Works
Sermorelin activates the GHRH receptor (GHRH-R) on cells called somatotrophs in the anterior pituitary gland — the specialized cells that manufacture and release growth hormone. When the compound binds that receptor, it triggers an intracellular signaling cascade through a pathway called cAMP/PKA (cyclic AMP and protein kinase A), the same cascade the body's own GHRH uses¹˒².
Think of it like a doorbell. The peptide rings the same doorbell the hypothalamus rings every night during deep sleep. The pituitary answers the same way it always does: by releasing a pulse of growth hormone into the blood.
The Somatostatin Brake
This is the structural distinction between sermorelin and direct growth hormone injection (rhGH): sermorelin stays subject to the body's built-in feedback system.
When GH and IGF-1 levels rise in the blood, the hypothalamus releases somatostatin (sometimes called growth hormone-inhibiting hormone) — a brake that signals the pituitary to slow GH release². The compound can ring the doorbell as often as it likes, but with the brake engaged the pituitary answers less vigorously.
Exogenous growth hormone (rhGH) bypasses this feedback entirely. The injected hormone is GH itself, so the pituitary's regulatory state does not enter into it — circulating GH rises regardless of the feedback system. This is the mechanism behind rhGH's capacity for supraphysiological GH levels, and the reason sermorelin's GH output stays bounded by the intact feedback loop².
As Walker (2006) noted in Clinical Interventions in Aging, the drug "simulates the patient's own pituitary gland by binding to specific receptors to increase production and secretion of endogenous hGH," preserving the pulsatile pattern that characterizes healthy GH physiology².
Receptor Selectivity
Sermorelin's selectivity profile is narrow. At physiological doses, the cited data record no elevation of cortisol, ACTH (the stress hormone pathway), or prolactin². That marks a distinction from some other GH-stimulating compounds — particularly the older ghrelin-receptor agonists like GHRP-2 and GHRP-6, which can raise cortisol and stimulate appetite as off-target effects. The compound stays in its lane: it activates the GHRH receptor, triggers GH release, and does not significantly touch other hormonal axes.
The FDA Story: Approval, Withdrawal, and Why It Matters Now
This is the part of sermorelin's history that almost nobody tells — and it's arguably the most important context for understanding its current place in the GH secretagogue landscape.
1997: FDA Approval
Sermorelin was approved by the FDA in 1997 under the brand name Geref. The approved indication was for the diagnosis and treatment of idiopathic growth hormone deficiency in children³˒⁴. The approval was based on clinical trials demonstrating that it produced significant increases in height velocity — the rate at which children grow — sustained over 12 months, with preliminary data extending to 36 months³˒⁴.
The compound was not as effective as recombinant human growth hormone (rhGH) at equivalent doses. In head-to-head comparisons at 30 mcg/kg/day, rhGH produced greater height velocity⁴. But sermorelin offered something rhGH couldn't: physiological regulation. Because it works through the pituitary rather than bypassing it, it preserved normal feedback mechanisms and pulsatile GH patterns. For some clinicians, particularly those treating milder GH deficiency, this trade-off — slightly less potency in exchange for a more physiological approach — was worth making.
2008: Commercial Withdrawal
In 2008, EMD Serono (the manufacturer) withdrew Geref from the commercial market, citing manufacturing difficulties for a niche peptide competing against rhGH products already entrenched in pediatric endocrinology practices¹˒⁴.
The withdrawal was a commercial action by the manufacturer, not a safety action: the FDA did not pull sermorelin over adverse events, toxicity signals, or new risk data, and the compound's safety profile remained intact. The prior FDA approval was never revoked.
How the FDA History Shapes the Regulatory Position
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can legally produce medications using bulk drug substances that meet certain criteria. One of the clearest pathways is for compounds that were previously FDA-approved⁵.
Sermorelin fits that pathway. It was FDA-approved, it was not withdrawn for safety, and it remains a recognized pharmaceutical compound carrying the data record from its years on the commercial market.
The contrast with other popular GH secretagogues is documented. CJC-1295 (without DAC) has never been in a human clinical trial and has no FDA history. Ipamorelin reached Phase II trials but for a different indication (postoperative ileus) and was never approved. Both compounds were briefly placed on the FDA's Category 2 list in 2024 — which would have prohibited compounding — before being removed when their nominators withdrew⁶. As of early 2026, they sit outside that list: not explicitly banned, not on the approved bulks list either.
Sermorelin's compounding pathway rests on prior FDA approval under the 503A framework⁵ — the point the practitioner and pharmacy literature keeps returning to when it compares the class.
Clinical Evidence: What We Know and What We Don't Know
Honest assessment of sermorelin's evidence base requires separating two distinct bodies of data: pediatric trials that supported FDA approval, and adult data that are far thinner than most wellness sources acknowledge.
Pediatric Evidence: Adequate for Approval
The pediatric data were sufficient for FDA approval and showed clear efficacy. Children with idiopathic GH deficiency treated with the compound demonstrated significant increases in height velocity over 12-month treatment periods, with longer-term data extending to 36 months³˒⁴. These trials established that sermorelin could meaningfully stimulate endogenous GH release through the pituitary and produce clinically relevant outcomes.
The limitation: it was consistently less effective than rhGH at equivalent doses⁴. This is pharmacologically expected — activating the GHRH receptor to stimulate pituitary GH release is inherently less potent than injecting GH directly. The trade-off is physiological regulation versus raw potency.
Adult Evidence: One Small Trial
Here's where intellectual honesty demands uncomfortable transparency.
The entire body of adult clinical evidence for sermorelin essentially rests on a single trial: Khorram et al. (1997), published in the Journal of Clinical Endocrinology & Metabolism⁷.
The study design: 19 elderly subjects (ages 55-71), treated with a GHRH analog for 16 weeks, single-blind.
What improved:
- Nocturnal GH secretion increased significantly (P<0.01 in women, P<0.05 in men)
- IGF-1 increased (P<0.05)
- IGFBP-3 increased (P<0.001)
- Lean body mass improved in men only (P<0.05) — an increase of approximately 1.26 kg
What didn't change:
- Total body fat — no significant change in either sex
- BMI — no significant change
- Bone mineral density — no significant change
- Lean body mass in women — no significant change
The limitations are substantial: 19 subjects. Single-blind design (not double-blind). Gender-discordant results — lean mass improved in men but not women. Sixteen weeks of treatment, which may be too short to observe changes in fat mass or bone density. No functional endpoints (strength, exercise capacity, quality of life)⁷.
This trial is the source of virtually every "sermorelin increases lean muscle mass" claim on wellness websites. And the data do support that claim — in elderly men, over 16 weeks, in a sample of fewer than 10 men. Whether the finding generalizes to the broader population seeking the compound in 2026 — typically 35-55-year-old fitness-oriented adults — is genuinely unknown.
What the Evidence Hierarchy Looks Like
To put sermorelin's adult evidence in perspective within the GH secretagogue class:
| Compound | Best Adult Evidence | Sample Size | Duration | Key Outcome |
|---|---|---|---|---|
| Tesamorelin | Phase III RCTs (LIPO-010/1011) | N=816 | 26-52 wks | 15-20% VAT reduction vs placebo |
| MK-677 | 2-year RCT (Nass 2008) | N=65 | 2 years | +1.1 kg lean mass, no strength improvement |
| Sermorelin | Single trial (Khorram 1997) | N=19 | 16 weeks | +1.26 kg lean mass (men only), no fat/BMD changes |
| Ipamorelin | PK/PD characterization only | 200–300 mcg | 8–12 wks | No body composition RCT, but widely used in clinical practice at 200 mcg/day SubQ before bed |
| CJC-1295 no-DAC | No human trials | 100–300 mcg | 8–16 wks | No published efficacy data. Practitioner protocols: 200 mcg SubQ nightly, fasted, typically stacked with Ipamorelin |
⁸˒⁹˒⁷˒¹⁰
This table isn't meant to discourage — it's meant to calibrate expectations. Sermorelin has more adult clinical data than ipamorelin or CJC-1295 without DAC (both of which have zero body composition trial data). But it has dramatically less evidence than tesamorelin, which went through the full Phase III regulatory gauntlet. For a deeper comparison, see our tesamorelin deep dive.
Sermorelin Benefits: Separating Evidence from Marketing
The benefits listed on wellness sites — improved sleep, better recovery, lean mass preservation, fat loss, anti-aging — range from plausible to unsupported when measured against actual published data. Here is the honest breakdown.
Supported by Direct Evidence
GH and IGF-1 elevation: Sermorelin reliably increases nocturnal GH secretion and raises IGF-1 levels. This is demonstrated in both pediatric and adult populations⁷˒³˒⁴. There is no serious debate about whether it works at the receptor level — it does.
Lean body mass (limited): The Khorram trial showed a statistically significant improvement in lean body mass in elderly men over 16 weeks⁷. This is real data, though the small sample, single-sex finding, and absence of replication bound how far it carries.
Supported by Mechanism but Not Direct Trial Data
Sleep quality: GH secretion is intimately linked to slow-wave (deep) sleep. Compounds that increase GH pulsatility — particularly when dosed at bedtime — have a plausible mechanism for improving sleep architecture. MK-677, a different GH secretagogue, showed a 50% increase in Stage 4 sleep in published studies¹¹. Sermorelin's bedtime dosing is designed to leverage this same physiological window, but no published trial has measured its sleep outcomes directly.
Recovery and tissue repair: GH and IGF-1 support protein synthesis, collagen turnover, and tissue repair. These are well-established physiological effects of the GH/IGF-1 axis. Whether the compound's modest GH elevation produces clinically meaningful improvements in recovery is plausible but unquantified in published research.
Frequently Claimed but Not Supported by Evidence
Fat loss: The Khorram trial found no significant change in total body fat or BMI⁷. This doesn't mean sermorelin can't contribute to fat loss in the right context (caloric deficit, exercise), but the direct evidence for an independent fat-reducing effect simply isn't there.
Anti-aging effects: The broader GH secretagogue class has struggled to demonstrate functional improvements beyond surrogate markers. MK-677's two-year trial increased lean mass but not strength or function⁹. Anamorelin's Phase III trials increased lean mass but not handgrip strength¹². The pattern across the class raises a legitimate question: does GH-axis stimulation alone translate into the outcomes people actually care about?
Side Effects
Sermorelin's adverse events were characterized over its years as an FDA-approved product.
The most commonly reported are transient facial flushing and injection site reactions (redness, mild pain at the injection site)¹˒⁴. Mild peripheral edema (fluid retention) and tingling were recorded less frequently than with more potent GHRH analogs like tesamorelin¹.
At standard doses, the cited data record no elevation of cortisol, ACTH, or prolactin² — a profile that separates it from ghrelin-receptor agonists like GHRP-2 and GHRP-6, which can affect these hormonal axes.
The somatostatin feedback mechanism bounds the GH response: because the peptide works through the pituitary's natural regulatory system, GH output stays tied to that loop rather than climbing independently of it².
Extended use raises GH and IGF-1, which is what IGF-1 monitoring tracks — periodic testing reads whether levels stay within a physiological range.
Sermorelin vs Tesamorelin
Both sermorelin and tesamorelin are GHRH receptor agonists — they ring the same doorbell on the same pituitary cells. The differences lie in structure, potency, evidence base, and regulatory status.
Structural difference: Sermorelin is the first 29 amino acids of GHRH (GRF 1-29) with no structural modifications. Tesamorelin retains the full 44-amino-acid GHRH sequence and adds a trans-3-hexenoic acid group to the N-terminus, which protects it against enzymatic degradation by DPP-IV (dipeptidyl peptidase-IV, the enzyme that rapidly breaks down native GHRH)¹³˒¹⁴. This gives tesamorelin modestly better metabolic stability, though both compounds have short half-lives in the range of 10-38 minutes.
Evidence gap: The clinical evidence difference is stark. Tesamorelin has two Phase III RCTs totaling 816 patients with CT-measured visceral fat outcomes. Sermorelin has one adult trial with 19 subjects⁷˒⁸˒¹⁴. For anyone making evidence-based decisions, this gap is the primary differentiator.
Regulatory status: Tesamorelin is currently FDA-approved (brand name Egrifta) for HIV-associated lipodystrophy. Sermorelin was FDA-approved but is commercially withdrawn. Both are legally compoundable, though through slightly different regulatory pathways.
Tolerability: Edema and tingling were recorded less frequently with sermorelin than with tesamorelin's more robust GH stimulation¹.
The practical question: If tesamorelin has the stronger evidence, what accounts for sermorelin's continued use? Three factors recur in the practitioner literature: (1) the lower edema and tingling frequency in edema-sensitive individuals, (2) lower cost through compounding pharmacies, and (3) a milder GH stimulus that fits goals short of maximal potency — recovery support during moderate caloric restriction, for example, rather than aggressive visceral fat reduction.
For a comprehensive comparison across the full GH secretagogue class, see our GH secretagogue comparison guide.
Legal Status and Compounding
Among GH secretagogues available through compounding pharmacies, sermorelin's regulatory position is the most documented.
The 503A pathway: Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound medications for individual patients based on a valid prescription. Compounds that were previously FDA-approved hold a defined standing under this framework. Sermorelin, with its 1997 FDA approval and non-safety-related withdrawal, fits this pathway⁵.
Comparison to other GH secretagogues: CJC-1295 (without DAC) and ipamorelin currently sit in regulatory uncertainty. Neither was ever FDA-approved. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed ipamorelin in October 2024 and declined to recommend it for the 503A Bulks List⁶. As of early 2026, neither compound is explicitly banned from compounding, and neither carries sermorelin's prior-approval footing.
Enforcement context: FDA enforcement against compounded peptides tightened measurably in late 2024, with warning letters issued to several peptide suppliers and over 40 state attorneys general co-signing demands for a federal crackdown on compounded peptides⁶. That enforcement push primarily targeted GLP-1 agonists (semaglutide, tirzepatide), but the regulatory infrastructure being built reaches wider. Sermorelin's prior FDA approval separates its standing from the other GH secretagogues under that trend. For context on how the regulatory landscape has affected other compounds, see our BPC-157 guide.
Prescription requirement: The drug is available through compounding pharmacies by prescription only. It is classified as a research compound in non-prescription contexts and is prohibited by WADA for competitive athletes.
Frequently Asked Questions
Is sermorelin FDA-approved?
It was FDA-approved in 1997 under the brand name Geref for pediatric growth hormone deficiency. The manufacturer (EMD Serono) withdrew it from the commercial market in 2008 due to manufacturing and business considerations, not safety concerns¹˒⁴. It is currently available through compounding pharmacies with a prescription.
How long does it take for sermorelin to work?
The acute GH-stimulating effects occur within hours of injection. In the Khorram 1997 trial, significant increases in nocturnal GH secretion and IGF-1 were measurable over the 16-week study period⁷. Anecdotally, clinicians report that sleep quality improvements may be noticeable within 1-2 weeks, while body composition changes typically require 8-12 weeks of consistent use, though these timelines come from clinical practice rather than controlled studies. Use our reconstitution calculator for precise mixing.
What is the difference between sermorelin and HGH?
Sermorelin stimulates the pituitary gland to produce and release its own growth hormone, preserving the body's natural pulsatile rhythm and somatostatin feedback. Recombinant human growth hormone (rhGH) is the hormone itself — injecting it bypasses the pituitary entirely. The consequence: rhGH can produce supraphysiological GH levels because it does not pass through the feedback loop, while sermorelin's GH output stays bounded by that loop².
Can you take sermorelin long-term?
Long-term safety data in adults are limited. The longest adult trial was 16 weeks⁷. The compound showed IGF-1 elevations that persisted above baseline two weeks after cessation in elderly men, suggesting no immediate rebound effect¹¹. Clinical practice commonly employs cycling protocols (8-12 weeks on, 2-4 weeks off), though these are derived from practitioner experience rather than published dose-duration optimization studies.
Related Topics
- GH Secretagogue Comparison — evidence rankings for every GH peptide
- Tesamorelin Guide — GHRH analog with visceral fat data
- DSIP Guide — deepens the slow-wave sleep window where GH pulses fire
- Injury Recovery Protocol — GH secretagogues as support layer for overnight recovery
References
¹ DrugBank pharmacology profile — DrugBank. "Sermorelin (DB00010)." DrugBank DB00010
² GH insufficiency management review — Walker RF. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308. PMC2699646
³ Pediatric GHD diagnosis and treatment — Keating GM, Wellington K. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic GHD." BioDrugs. 2004;18(5):339-354. PubMed 18031173
⁴ FDA approval history and pediatric trials — Keating GM, Wellington K. 2004 (same source as ³; cited separately for FDA approval history and pediatric clinical trial data sections).
⁵ 503A compounding legal framework — Frier Levitt. "Regulatory Status of Peptide Compounding in 2025." Frier Levitt
⁶ FDA Category 2 list and enforcement — Alpha Rejuvenation. "Peptides No Longer on FDA Category 2 List." 2024; PeptideExaminer. "The FDA's War on Peptides." 2025.
⁷ Khorram adult GHRH trial (N=19) — Khorram O et al. "Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women." Journal of Clinical Endocrinology & Metabolism. 1997;82(5):1472-1479. PubMed 9141536
⁸ Tesamorelin pooled Phase III (N=816) — Falutz J et al. "Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled Phase 3 analysis." Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304. PubMed 20554713
⁹ MK-677 two-year body composition RCT — Nass R et al. "Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults." Annals of Internal Medicine. 2008. PMC2757071
¹⁰ GH secretagogues and body composition review — Sinha DK et al. "Beyond the androgen receptor: GH secretagogues in body composition." Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. PMC7108996
¹¹ GH secretagogue safety and efficacy review — Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews. 2018;6(1):45-53. PMC5632578
¹² Anamorelin cachexia approval — Wakabayashi H et al. "The regulatory approval of anamorelin for cachexia in Japan." 2021. PMC7890143
¹³ Egrifta prescribing information — FDA Egrifta Prescribing Information (2025 label). FDA Label
¹⁴ Tesamorelin NEJM pivotal trial — Falutz J et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. PubMed 18057338
Foundational Reviews
- Alba-Roth J, Muller OA, et al. "Sermorelin: a review of its pharmacology and efficacy in growth hormone deficiency." Drugs. 1988. PMID 2545260
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.